nodes	percent_of_prediction	percent_of_DWPC	metapath
Carbinoxamine—CYP2E1—prostate cancer	0.128	0.382	CbGaD
Carbinoxamine—CYP2C19—prostate cancer	0.127	0.378	CbGaD
Carbinoxamine—CYP3A4—prostate cancer	0.0806	0.24	CbGaD
Carbinoxamine—CYP2C8—Nilutamide—prostate cancer	0.0274	0.0585	CbGbCtD
Carbinoxamine—CYP2C19—Bicalutamide—prostate cancer	0.023	0.0491	CbGbCtD
Carbinoxamine—CYP2C19—Nilutamide—prostate cancer	0.023	0.0491	CbGbCtD
Carbinoxamine—CYP2C8—Abiraterone—prostate cancer	0.0227	0.0485	CbGbCtD
Carbinoxamine—CYP2E1—Estrone—prostate cancer	0.022	0.0469	CbGbCtD
Carbinoxamine—CYP2B6—Estrone—prostate cancer	0.0217	0.0463	CbGbCtD
Carbinoxamine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0212	0.0451	CbGbCtD
Carbinoxamine—CYP2B6—Ethinyl Estradiol—prostate cancer	0.0193	0.0412	CbGbCtD
Carbinoxamine—CYP2C9—Bicalutamide—prostate cancer	0.0191	0.0408	CbGbCtD
Carbinoxamine—CYP2C9—Nilutamide—prostate cancer	0.0191	0.0408	CbGbCtD
Carbinoxamine—CYP2C19—Flutamide—prostate cancer	0.0191	0.0407	CbGbCtD
Carbinoxamine—CYP2D6—Bicalutamide—prostate cancer	0.0175	0.0373	CbGbCtD
Carbinoxamine—CYP2C8—Cabazitaxel—prostate cancer	0.0168	0.0358	CbGbCtD
Carbinoxamine—CYP2C8—Ethinyl Estradiol—prostate cancer	0.0146	0.0312	CbGbCtD
Carbinoxamine—CYP2D6—Abiraterone—prostate cancer	0.0145	0.0309	CbGbCtD
Carbinoxamine—CYP2E1—Mitoxantrone—prostate cancer	0.0131	0.0279	CbGbCtD
Carbinoxamine—CYP2C9—Estrone—prostate cancer	0.0115	0.0244	CbGbCtD
Carbinoxamine—CYP3A4—Bicalutamide—prostate cancer	0.0111	0.0237	CbGbCtD
Carbinoxamine—CYP3A4—Estramustine—prostate cancer	0.0103	0.022	CbGbCtD
Carbinoxamine—CYP2C8—Estradiol—prostate cancer	0.00943	0.0201	CbGbCtD
Carbinoxamine—CYP3A4—Flutamide—prostate cancer	0.00921	0.0197	CbGbCtD
Carbinoxamine—CYP3A4—Abiraterone—prostate cancer	0.00921	0.0197	CbGbCtD
Carbinoxamine—CYP2C9—Capecitabine—prostate cancer	0.00868	0.0185	CbGbCtD
Carbinoxamine—CYP2E1—Etoposide—prostate cancer	0.00824	0.0176	CbGbCtD
Carbinoxamine—CYP2C19—Estradiol—prostate cancer	0.00791	0.0169	CbGbCtD
Carbinoxamine—CYP3A4—Cabazitaxel—prostate cancer	0.00682	0.0145	CbGbCtD
Carbinoxamine—CYP2C19—Prednisone—prostate cancer	0.00681	0.0145	CbGbCtD
Carbinoxamine—CYP3A4—Estrone—prostate cancer	0.00666	0.0142	CbGbCtD
Carbinoxamine—CYP2C9—Estradiol—prostate cancer	0.00658	0.014	CbGbCtD
Carbinoxamine—CYP2C8—Etoposide—prostate cancer	0.00616	0.0131	CbGbCtD
Carbinoxamine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00594	0.0127	CbGbCtD
Carbinoxamine—CYP2B6—Doxorubicin—prostate cancer	0.00555	0.0118	CbGbCtD
Carbinoxamine—CYP3A4—Conjugated Estrogens—prostate cancer	0.00436	0.00929	CbGbCtD
Carbinoxamine—CYP3A4—Mitoxantrone—prostate cancer	0.00396	0.00845	CbGbCtD
Carbinoxamine—CYP3A4—Estradiol—prostate cancer	0.00383	0.00816	CbGbCtD
Carbinoxamine—CYP3A4—Prednisone—prostate cancer	0.00329	0.00702	CbGbCtD
Carbinoxamine—CYP2D6—Doxorubicin—prostate cancer	0.00268	0.00572	CbGbCtD
Carbinoxamine—CYP3A4—Etoposide—prostate cancer	0.0025	0.00533	CbGbCtD
Carbinoxamine—CYP3A4—Docetaxel—prostate cancer	0.00229	0.00488	CbGbCtD
Carbinoxamine—CYP2C19—urine—prostate cancer	0.00175	0.153	CbGeAlD
Carbinoxamine—CYP3A4—Doxorubicin—prostate cancer	0.0017	0.00363	CbGbCtD
Carbinoxamine—CYP2C9—urine—prostate cancer	0.00136	0.118	CbGeAlD
Carbinoxamine—CYP2E1—urine—prostate cancer	0.00129	0.112	CbGeAlD
Carbinoxamine—CYP3A4—urine—prostate cancer	0.00104	0.0902	CbGeAlD
Carbinoxamine—CYP2D6—urine—prostate cancer	0.00102	0.0887	CbGeAlD
Carbinoxamine—HRH1—prostate gland—prostate cancer	0.000481	0.0419	CbGeAlD
Carbinoxamine—CYP2E1—prostate gland—prostate cancer	0.000462	0.0402	CbGeAlD
Carbinoxamine—CYP2E1—seminal vesicle—prostate cancer	0.000391	0.034	CbGeAlD
Carbinoxamine—CYP2C8—renal system—prostate cancer	0.000374	0.0326	CbGeAlD
Carbinoxamine—Mitotane—SHBG—prostate cancer	0.000361	0.201	CrCbGaD
Carbinoxamine—HRH1—epithelium—prostate cancer	0.000353	0.0308	CbGeAlD
Carbinoxamine—CYP2B6—renal system—prostate cancer	0.000336	0.0292	CbGeAlD
Carbinoxamine—HRH1—urethra—prostate cancer	0.000322	0.028	CbGeAlD
Carbinoxamine—CYP2E1—renal system—prostate cancer	0.000315	0.0274	CbGeAlD
Carbinoxamine—CYP2E1—urethra—prostate cancer	0.000309	0.0269	CbGeAlD
Carbinoxamine—CYP3A4—renal system—prostate cancer	0.000253	0.0221	CbGeAlD
Carbinoxamine—CYP2D6—renal system—prostate cancer	0.000249	0.0217	CbGeAlD
Carbinoxamine—CYP2C8—testis—prostate cancer	0.000242	0.0211	CbGeAlD
Carbinoxamine—CYP2B6—testis—prostate cancer	0.000217	0.0189	CbGeAlD
Carbinoxamine—HRH1—testis—prostate cancer	0.000212	0.0184	CbGeAlD
Carbinoxamine—CYP2E1—testis—prostate cancer	0.000204	0.0177	CbGeAlD
Carbinoxamine—Insomnia—Conjugated Estrogens—prostate cancer	0.00017	0.00189	CcSEcCtD
Carbinoxamine—Agitation—Estradiol—prostate cancer	0.000169	0.00188	CcSEcCtD
Carbinoxamine—Paraesthesia—Conjugated Estrogens—prostate cancer	0.000168	0.00187	CcSEcCtD
Carbinoxamine—Somnolence—Goserelin—prostate cancer	0.000168	0.00187	CcSEcCtD
Carbinoxamine—Chlorphenamine—SLC22A1—prostate cancer	0.000167	0.0933	CrCbGaD
Carbinoxamine—Somnolence—Conjugated Estrogens—prostate cancer	0.000167	0.00186	CcSEcCtD
Carbinoxamine—Dyspepsia—Goserelin—prostate cancer	0.000167	0.00185	CcSEcCtD
Carbinoxamine—Vertigo—Estradiol—prostate cancer	0.000165	0.00184	CcSEcCtD
Carbinoxamine—Dyspepsia—Conjugated Estrogens—prostate cancer	0.000165	0.00184	CcSEcCtD
Carbinoxamine—Asthenia—Ethinyl Estradiol—prostate cancer	0.000165	0.00184	CcSEcCtD
Carbinoxamine—Decreased appetite—Goserelin—prostate cancer	0.000165	0.00183	CcSEcCtD
Carbinoxamine—Fatigue—Goserelin—prostate cancer	0.000163	0.00182	CcSEcCtD
Carbinoxamine—Decreased appetite—Conjugated Estrogens—prostate cancer	0.000163	0.00181	CcSEcCtD
Carbinoxamine—Palpitations—Estradiol—prostate cancer	0.000163	0.00181	CcSEcCtD
Carbinoxamine—Irritability—Prednisone—prostate cancer	0.000162	0.0018	CcSEcCtD
Carbinoxamine—Constipation—Goserelin—prostate cancer	0.000162	0.0018	CcSEcCtD
Carbinoxamine—Fatigue—Conjugated Estrogens—prostate cancer	0.000162	0.0018	CcSEcCtD
Carbinoxamine—Nausea—Bicalutamide—prostate cancer	0.000162	0.0018	CcSEcCtD
Carbinoxamine—Vision blurred—Mitoxantrone—prostate cancer	0.000162	0.0018	CcSEcCtD
Carbinoxamine—CYP2D6—testis—prostate cancer	0.000161	0.014	CbGeAlD
Carbinoxamine—Constipation—Conjugated Estrogens—prostate cancer	0.00016	0.00178	CcSEcCtD
Carbinoxamine—Sweating increased—Capecitabine—prostate cancer	0.00016	0.00178	CcSEcCtD
Carbinoxamine—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000157	0.00175	CcSEcCtD
Carbinoxamine—Feeling abnormal—Goserelin—prostate cancer	0.000156	0.00174	CcSEcCtD
Carbinoxamine—HRH1—lymph node—prostate cancer	0.000154	0.0134	CbGeAlD
Carbinoxamine—Dizziness—Ethinyl Estradiol—prostate cancer	0.000152	0.00169	CcSEcCtD
Carbinoxamine—Confusional state—Estradiol—prostate cancer	0.000151	0.00168	CcSEcCtD
Carbinoxamine—Photosensitivity—Epirubicin—prostate cancer	0.000151	0.00168	CcSEcCtD
Carbinoxamine—Urticaria—Goserelin—prostate cancer	0.00015	0.00167	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Capecitabine—prostate cancer	0.00015	0.00167	CcSEcCtD
Carbinoxamine—Urticaria—Conjugated Estrogens—prostate cancer	0.000149	0.00166	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Docetaxel—prostate cancer	0.000149	0.00165	CcSEcCtD
Carbinoxamine—Convulsion—Mitoxantrone—prostate cancer	0.000148	0.00165	CcSEcCtD
Carbinoxamine—Chills—Etoposide—prostate cancer	0.000147	0.00163	CcSEcCtD
Carbinoxamine—Tachycardia—Estradiol—prostate cancer	0.000147	0.00163	CcSEcCtD
Carbinoxamine—Vomiting—Ethinyl Estradiol—prostate cancer	0.000146	0.00163	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Estradiol—prostate cancer	0.000145	0.00161	CcSEcCtD
Carbinoxamine—Headache—Ethinyl Estradiol—prostate cancer	0.000144	0.0016	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Capecitabine—prostate cancer	0.000144	0.0016	CcSEcCtD
Carbinoxamine—Sweating increased—Prednisone—prostate cancer	0.000143	0.00159	CcSEcCtD
Carbinoxamine—Agranulocytosis—Docetaxel—prostate cancer	0.000141	0.00157	CcSEcCtD
Carbinoxamine—Confusional state—Mitoxantrone—prostate cancer	0.000141	0.00157	CcSEcCtD
Carbinoxamine—Photosensitivity—Doxorubicin—prostate cancer	0.00014	0.00156	CcSEcCtD
Carbinoxamine—Diphenhydramine—CYP2C18—prostate cancer	0.000139	0.0775	CrCbGaD
Carbinoxamine—Agranulocytosis—Capecitabine—prostate cancer	0.000137	0.00152	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Mitoxantrone—prostate cancer	0.000137	0.00152	CcSEcCtD
Carbinoxamine—Nausea—Ethinyl Estradiol—prostate cancer	0.000137	0.00152	CcSEcCtD
Carbinoxamine—Tachycardia—Mitoxantrone—prostate cancer	0.000137	0.00152	CcSEcCtD
Carbinoxamine—Asthenia—Goserelin—prostate cancer	0.000136	0.00151	CcSEcCtD
Carbinoxamine—Clomipramine—GSTP1—prostate cancer	0.000136	0.0757	CrCbGaD
Carbinoxamine—Insomnia—Estradiol—prostate cancer	0.000136	0.00151	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Mitoxantrone—prostate cancer	0.000135	0.0015	CcSEcCtD
Carbinoxamine—Chlorphenamine—CYP3A5—prostate cancer	0.000135	0.0753	CrCbGaD
Carbinoxamine—Paraesthesia—Estradiol—prostate cancer	0.000135	0.0015	CcSEcCtD
Carbinoxamine—Asthenia—Conjugated Estrogens—prostate cancer	0.000135	0.0015	CcSEcCtD
Carbinoxamine—Somnolence—Estradiol—prostate cancer	0.000133	0.00148	CcSEcCtD
Carbinoxamine—Anorexia—Mitoxantrone—prostate cancer	0.000133	0.00148	CcSEcCtD
Carbinoxamine—Diplopia—Epirubicin—prostate cancer	0.000133	0.00148	CcSEcCtD
Carbinoxamine—Dyspepsia—Estradiol—prostate cancer	0.000132	0.00147	CcSEcCtD
Carbinoxamine—Hypotension—Mitoxantrone—prostate cancer	0.000131	0.00145	CcSEcCtD
Carbinoxamine—Decreased appetite—Estradiol—prostate cancer	0.00013	0.00145	CcSEcCtD
Carbinoxamine—Diarrhoea—Goserelin—prostate cancer	0.00013	0.00144	CcSEcCtD
Carbinoxamine—Fatigue—Estradiol—prostate cancer	0.000129	0.00144	CcSEcCtD
Carbinoxamine—Constipation—Estradiol—prostate cancer	0.000128	0.00143	CcSEcCtD
Carbinoxamine—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000128	0.00143	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Prednisone—prostate cancer	0.000128	0.00143	CcSEcCtD
Carbinoxamine—Vertigo—Etoposide—prostate cancer	0.000128	0.00142	CcSEcCtD
Carbinoxamine—Paraesthesia—Mitoxantrone—prostate cancer	0.000126	0.0014	CcSEcCtD
Carbinoxamine—Dizziness—Goserelin—prostate cancer	0.000125	0.00139	CcSEcCtD
Carbinoxamine—Somnolence—Mitoxantrone—prostate cancer	0.000124	0.00138	CcSEcCtD
Carbinoxamine—Dizziness—Conjugated Estrogens—prostate cancer	0.000124	0.00138	CcSEcCtD
Carbinoxamine—Feeling abnormal—Estradiol—prostate cancer	0.000124	0.00138	CcSEcCtD
Carbinoxamine—Convulsion—Etoposide—prostate cancer	0.000124	0.00137	CcSEcCtD
Carbinoxamine—Dyspepsia—Mitoxantrone—prostate cancer	0.000123	0.00137	CcSEcCtD
Carbinoxamine—Tinnitus—Capecitabine—prostate cancer	0.000123	0.00137	CcSEcCtD
Carbinoxamine—Diplopia—Doxorubicin—prostate cancer	0.000123	0.00137	CcSEcCtD
Carbinoxamine—Chills—Docetaxel—prostate cancer	0.000122	0.00136	CcSEcCtD
Carbinoxamine—Decreased appetite—Mitoxantrone—prostate cancer	0.000122	0.00135	CcSEcCtD
Carbinoxamine—Fatigue—Mitoxantrone—prostate cancer	0.000121	0.00134	CcSEcCtD
Carbinoxamine—Vomiting—Goserelin—prostate cancer	0.00012	0.00134	CcSEcCtD
Carbinoxamine—Constipation—Mitoxantrone—prostate cancer	0.00012	0.00133	CcSEcCtD
Carbinoxamine—Vomiting—Conjugated Estrogens—prostate cancer	0.000119	0.00133	CcSEcCtD
Carbinoxamine—Urticaria—Estradiol—prostate cancer	0.000119	0.00133	CcSEcCtD
Carbinoxamine—Headache—Goserelin—prostate cancer	0.000119	0.00132	CcSEcCtD
Carbinoxamine—Chills—Capecitabine—prostate cancer	0.000118	0.00132	CcSEcCtD
Carbinoxamine—Headache—Conjugated Estrogens—prostate cancer	0.000118	0.00131	CcSEcCtD
Carbinoxamine—Confusional state—Etoposide—prostate cancer	0.000117	0.00131	CcSEcCtD
Carbinoxamine—Feeling abnormal—Mitoxantrone—prostate cancer	0.000115	0.00128	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Etoposide—prostate cancer	0.000114	0.00127	CcSEcCtD
Carbinoxamine—Tachycardia—Etoposide—prostate cancer	0.000114	0.00126	CcSEcCtD
Carbinoxamine—Diphenhydramine—SLC22A1—prostate cancer	0.000114	0.0633	CrCbGaD
Carbinoxamine—Nausea—Goserelin—prostate cancer	0.000112	0.00125	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Etoposide—prostate cancer	0.000112	0.00125	CcSEcCtD
Carbinoxamine—Nausea—Conjugated Estrogens—prostate cancer	0.000111	0.00124	CcSEcCtD
Carbinoxamine—Urticaria—Mitoxantrone—prostate cancer	0.000111	0.00124	CcSEcCtD
Carbinoxamine—Anorexia—Etoposide—prostate cancer	0.000111	0.00123	CcSEcCtD
Carbinoxamine—Hypotension—Etoposide—prostate cancer	0.000109	0.00121	CcSEcCtD
Carbinoxamine—Vision blurred—Capecitabine—prostate cancer	0.000108	0.0012	CcSEcCtD
Carbinoxamine—Asthenia—Estradiol—prostate cancer	0.000108	0.0012	CcSEcCtD
Carbinoxamine—Tremor—Capecitabine—prostate cancer	0.000107	0.0012	CcSEcCtD
Carbinoxamine—Pollakiuria—Epirubicin—prostate cancer	0.000106	0.00118	CcSEcCtD
Carbinoxamine—Palpitations—Docetaxel—prostate cancer	0.000105	0.00116	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Epirubicin—prostate cancer	0.000105	0.00116	CcSEcCtD
Carbinoxamine—Paraesthesia—Etoposide—prostate cancer	0.000104	0.00116	CcSEcCtD
Carbinoxamine—Somnolence—Etoposide—prostate cancer	0.000103	0.00115	CcSEcCtD
Carbinoxamine—Vertigo—Capecitabine—prostate cancer	0.000103	0.00115	CcSEcCtD
Carbinoxamine—Diarrhoea—Estradiol—prostate cancer	0.000103	0.00114	CcSEcCtD
Carbinoxamine—Convulsion—Docetaxel—prostate cancer	0.000103	0.00114	CcSEcCtD
Carbinoxamine—Drowsiness—Epirubicin—prostate cancer	0.000102	0.00114	CcSEcCtD
Carbinoxamine—Palpitations—Capecitabine—prostate cancer	0.000101	0.00113	CcSEcCtD
Carbinoxamine—Decreased appetite—Etoposide—prostate cancer	0.000101	0.00113	CcSEcCtD
Carbinoxamine—Asthenia—Mitoxantrone—prostate cancer	0.0001	0.00112	CcSEcCtD
Carbinoxamine—Fatigue—Etoposide—prostate cancer	0.0001	0.00112	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Epirubicin—prostate cancer	0.0001	0.00112	CcSEcCtD
Carbinoxamine—Constipation—Etoposide—prostate cancer	9.95e-05	0.00111	CcSEcCtD
Carbinoxamine—Dizziness—Estradiol—prostate cancer	9.93e-05	0.0011	CcSEcCtD
Carbinoxamine—Pollakiuria—Doxorubicin—prostate cancer	9.8e-05	0.00109	CcSEcCtD
Carbinoxamine—Confusional state—Docetaxel—prostate cancer	9.75e-05	0.00108	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Doxorubicin—prostate cancer	9.69e-05	0.00108	CcSEcCtD
Carbinoxamine—Vision blurred—Prednisone—prostate cancer	9.63e-05	0.00107	CcSEcCtD
Carbinoxamine—Feeling abnormal—Etoposide—prostate cancer	9.59e-05	0.00107	CcSEcCtD
Carbinoxamine—Diarrhoea—Mitoxantrone—prostate cancer	9.57e-05	0.00106	CcSEcCtD
Carbinoxamine—Vomiting—Estradiol—prostate cancer	9.54e-05	0.00106	CcSEcCtD
Carbinoxamine—Agranulocytosis—Epirubicin—prostate cancer	9.54e-05	0.00106	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Docetaxel—prostate cancer	9.47e-05	0.00105	CcSEcCtD
Carbinoxamine—Drowsiness—Doxorubicin—prostate cancer	9.46e-05	0.00105	CcSEcCtD
Carbinoxamine—Brompheniramine—CYP2E1—prostate cancer	9.45e-05	0.0527	CrCbGaD
Carbinoxamine—Confusional state—Capecitabine—prostate cancer	9.44e-05	0.00105	CcSEcCtD
Carbinoxamine—Tachycardia—Docetaxel—prostate cancer	9.44e-05	0.00105	CcSEcCtD
Carbinoxamine—Headache—Estradiol—prostate cancer	9.4e-05	0.00105	CcSEcCtD
Carbinoxamine—Agitation—Prednisone—prostate cancer	9.39e-05	0.00104	CcSEcCtD
Carbinoxamine—Brompheniramine—CYP2C19—prostate cancer	9.36e-05	0.0522	CrCbGaD
Carbinoxamine—Neuropathy peripheral—Doxorubicin—prostate cancer	9.27e-05	0.00103	CcSEcCtD
Carbinoxamine—Urticaria—Etoposide—prostate cancer	9.24e-05	0.00103	CcSEcCtD
Carbinoxamine—Anorexia—Docetaxel—prostate cancer	9.22e-05	0.00103	CcSEcCtD
Carbinoxamine—Vertigo—Prednisone—prostate cancer	9.18e-05	0.00102	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Capecitabine—prostate cancer	9.17e-05	0.00102	CcSEcCtD
Carbinoxamine—Tachycardia—Capecitabine—prostate cancer	9.14e-05	0.00102	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Capecitabine—prostate cancer	9.05e-05	0.00101	CcSEcCtD
Carbinoxamine—Hypotension—Docetaxel—prostate cancer	9.04e-05	0.00101	CcSEcCtD
Carbinoxamine—Anorexia—Capecitabine—prostate cancer	8.92e-05	0.000993	CcSEcCtD
Carbinoxamine—Nausea—Estradiol—prostate cancer	8.92e-05	0.000992	CcSEcCtD
Carbinoxamine—Vomiting—Mitoxantrone—prostate cancer	8.89e-05	0.000989	CcSEcCtD
Carbinoxamine—Convulsion—Prednisone—prostate cancer	8.85e-05	0.000985	CcSEcCtD
Carbinoxamine—Agranulocytosis—Doxorubicin—prostate cancer	8.83e-05	0.000982	CcSEcCtD
Carbinoxamine—Headache—Mitoxantrone—prostate cancer	8.76e-05	0.000975	CcSEcCtD
Carbinoxamine—Hypotension—Capecitabine—prostate cancer	8.75e-05	0.000973	CcSEcCtD
Carbinoxamine—Insomnia—Docetaxel—prostate cancer	8.75e-05	0.000973	CcSEcCtD
Carbinoxamine—Paraesthesia—Docetaxel—prostate cancer	8.68e-05	0.000966	CcSEcCtD
Carbinoxamine—Chlorpromazine—SLC22A1—prostate cancer	8.62e-05	0.048	CrCbGaD
Carbinoxamine—Somnolence—Docetaxel—prostate cancer	8.6e-05	0.000956	CcSEcCtD
Carbinoxamine—Tinnitus—Epirubicin—prostate cancer	8.56e-05	0.000952	CcSEcCtD
Carbinoxamine—Dyspepsia—Docetaxel—prostate cancer	8.51e-05	0.000947	CcSEcCtD
Carbinoxamine—Insomnia—Capecitabine—prostate cancer	8.47e-05	0.000942	CcSEcCtD
Carbinoxamine—Paraesthesia—Capecitabine—prostate cancer	8.41e-05	0.000935	CcSEcCtD
Carbinoxamine—Decreased appetite—Docetaxel—prostate cancer	8.41e-05	0.000935	CcSEcCtD
Carbinoxamine—Asthenia—Etoposide—prostate cancer	8.35e-05	0.000929	CcSEcCtD
Carbinoxamine—Fatigue—Docetaxel—prostate cancer	8.34e-05	0.000927	CcSEcCtD
Carbinoxamine—Nausea—Mitoxantrone—prostate cancer	8.31e-05	0.000924	CcSEcCtD
Carbinoxamine—Constipation—Docetaxel—prostate cancer	8.27e-05	0.00092	CcSEcCtD
Carbinoxamine—Dyspepsia—Capecitabine—prostate cancer	8.24e-05	0.000917	CcSEcCtD
Carbinoxamine—Chills—Epirubicin—prostate cancer	8.24e-05	0.000916	CcSEcCtD
Carbinoxamine—Tachycardia—Prednisone—prostate cancer	8.14e-05	0.000905	CcSEcCtD
Carbinoxamine—Decreased appetite—Capecitabine—prostate cancer	8.14e-05	0.000905	CcSEcCtD
Carbinoxamine—Fatigue—Capecitabine—prostate cancer	8.07e-05	0.000898	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Prednisone—prostate cancer	8.06e-05	0.000897	CcSEcCtD
Carbinoxamine—Constipation—Capecitabine—prostate cancer	8.01e-05	0.000891	CcSEcCtD
Carbinoxamine—Feeling abnormal—Docetaxel—prostate cancer	7.97e-05	0.000886	CcSEcCtD
Carbinoxamine—Diarrhoea—Etoposide—prostate cancer	7.96e-05	0.000886	CcSEcCtD
Carbinoxamine—Anorexia—Prednisone—prostate cancer	7.95e-05	0.000884	CcSEcCtD
Carbinoxamine—Tinnitus—Doxorubicin—prostate cancer	7.92e-05	0.000881	CcSEcCtD
Carbinoxamine—Tension—Epirubicin—prostate cancer	7.84e-05	0.000872	CcSEcCtD
Carbinoxamine—Nervousness—Epirubicin—prostate cancer	7.76e-05	0.000863	CcSEcCtD
Carbinoxamine—Feeling abnormal—Capecitabine—prostate cancer	7.71e-05	0.000858	CcSEcCtD
Carbinoxamine—Dizziness—Etoposide—prostate cancer	7.69e-05	0.000856	CcSEcCtD
Carbinoxamine—Chills—Doxorubicin—prostate cancer	7.62e-05	0.000848	CcSEcCtD
Carbinoxamine—Insomnia—Prednisone—prostate cancer	7.54e-05	0.000839	CcSEcCtD
Carbinoxamine—Vision blurred—Epirubicin—prostate cancer	7.53e-05	0.000838	CcSEcCtD
Carbinoxamine—Paraesthesia—Prednisone—prostate cancer	7.49e-05	0.000833	CcSEcCtD
Carbinoxamine—Urticaria—Capecitabine—prostate cancer	7.44e-05	0.000827	CcSEcCtD
Carbinoxamine—Vomiting—Etoposide—prostate cancer	7.4e-05	0.000823	CcSEcCtD
Carbinoxamine—Agitation—Epirubicin—prostate cancer	7.34e-05	0.000817	CcSEcCtD
Carbinoxamine—Dyspepsia—Prednisone—prostate cancer	7.34e-05	0.000817	CcSEcCtD
Carbinoxamine—Headache—Etoposide—prostate cancer	7.29e-05	0.000811	CcSEcCtD
Carbinoxamine—Tension—Doxorubicin—prostate cancer	7.26e-05	0.000807	CcSEcCtD
Carbinoxamine—Decreased appetite—Prednisone—prostate cancer	7.25e-05	0.000806	CcSEcCtD
Carbinoxamine—Fatigue—Prednisone—prostate cancer	7.19e-05	0.0008	CcSEcCtD
Carbinoxamine—Nervousness—Doxorubicin—prostate cancer	7.18e-05	0.000799	CcSEcCtD
Carbinoxamine—Vertigo—Epirubicin—prostate cancer	7.18e-05	0.000799	CcSEcCtD
Carbinoxamine—Constipation—Prednisone—prostate cancer	7.13e-05	0.000793	CcSEcCtD
Carbinoxamine—Palpitations—Epirubicin—prostate cancer	7.06e-05	0.000786	CcSEcCtD
Carbinoxamine—Vision blurred—Doxorubicin—prostate cancer	6.97e-05	0.000775	CcSEcCtD
Carbinoxamine—Asthenia—Docetaxel—prostate cancer	6.94e-05	0.000772	CcSEcCtD
Carbinoxamine—Convulsion—Epirubicin—prostate cancer	6.92e-05	0.00077	CcSEcCtD
Carbinoxamine—Nausea—Etoposide—prostate cancer	6.91e-05	0.000769	CcSEcCtD
Carbinoxamine—Clomipramine—CYP2C19—prostate cancer	6.9e-05	0.0385	CrCbGaD
Carbinoxamine—Feeling abnormal—Prednisone—prostate cancer	6.87e-05	0.000764	CcSEcCtD
Carbinoxamine—Agitation—Doxorubicin—prostate cancer	6.79e-05	0.000756	CcSEcCtD
Carbinoxamine—Asthenia—Capecitabine—prostate cancer	6.72e-05	0.000747	CcSEcCtD
Carbinoxamine—Vertigo—Doxorubicin—prostate cancer	6.64e-05	0.000739	CcSEcCtD
Carbinoxamine—Urticaria—Prednisone—prostate cancer	6.62e-05	0.000737	CcSEcCtD
Carbinoxamine—Diarrhoea—Docetaxel—prostate cancer	6.62e-05	0.000736	CcSEcCtD
Carbinoxamine—Confusional state—Epirubicin—prostate cancer	6.58e-05	0.000732	CcSEcCtD
Carbinoxamine—Palpitations—Doxorubicin—prostate cancer	6.53e-05	0.000727	CcSEcCtD
Carbinoxamine—Convulsion—Doxorubicin—prostate cancer	6.41e-05	0.000713	CcSEcCtD
Carbinoxamine—Diarrhoea—Capecitabine—prostate cancer	6.41e-05	0.000713	CcSEcCtD
Carbinoxamine—Dizziness—Docetaxel—prostate cancer	6.39e-05	0.000711	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Epirubicin—prostate cancer	6.39e-05	0.00071	CcSEcCtD
Carbinoxamine—Tachycardia—Epirubicin—prostate cancer	6.37e-05	0.000708	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Epirubicin—prostate cancer	6.3e-05	0.000701	CcSEcCtD
Carbinoxamine—Diphenhydramine—CYP2C19—prostate cancer	6.24e-05	0.0348	CrCbGaD
Carbinoxamine—Anorexia—Epirubicin—prostate cancer	6.22e-05	0.000692	CcSEcCtD
Carbinoxamine—Dizziness—Capecitabine—prostate cancer	6.19e-05	0.000689	CcSEcCtD
Carbinoxamine—Vomiting—Docetaxel—prostate cancer	6.15e-05	0.000684	CcSEcCtD
Carbinoxamine—Hypotension—Epirubicin—prostate cancer	6.09e-05	0.000678	CcSEcCtD
Carbinoxamine—Confusional state—Doxorubicin—prostate cancer	6.08e-05	0.000677	CcSEcCtD
Carbinoxamine—Headache—Docetaxel—prostate cancer	6.06e-05	0.000674	CcSEcCtD
Carbinoxamine—Asthenia—Prednisone—prostate cancer	5.98e-05	0.000666	CcSEcCtD
Carbinoxamine—Orphenadrine—CYP2E1—prostate cancer	5.95e-05	0.0332	CrCbGaD
Carbinoxamine—Brompheniramine—CYP3A4—prostate cancer	5.95e-05	0.0332	CrCbGaD
Carbinoxamine—Vomiting—Capecitabine—prostate cancer	5.95e-05	0.000662	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Doxorubicin—prostate cancer	5.91e-05	0.000657	CcSEcCtD
Carbinoxamine—Insomnia—Epirubicin—prostate cancer	5.9e-05	0.000656	CcSEcCtD
Carbinoxamine—Tachycardia—Doxorubicin—prostate cancer	5.89e-05	0.000655	CcSEcCtD
Carbinoxamine—Headache—Capecitabine—prostate cancer	5.86e-05	0.000652	CcSEcCtD
Carbinoxamine—Paraesthesia—Epirubicin—prostate cancer	5.86e-05	0.000652	CcSEcCtD
Carbinoxamine—Chlorphenamine—CYP3A4—prostate cancer	5.84e-05	0.0326	CrCbGaD
Carbinoxamine—Hyperhidrosis—Doxorubicin—prostate cancer	5.83e-05	0.000649	CcSEcCtD
Carbinoxamine—Somnolence—Epirubicin—prostate cancer	5.8e-05	0.000645	CcSEcCtD
Carbinoxamine—Anorexia—Doxorubicin—prostate cancer	5.75e-05	0.00064	CcSEcCtD
Carbinoxamine—Nausea—Docetaxel—prostate cancer	5.74e-05	0.000639	CcSEcCtD
Carbinoxamine—Dyspepsia—Epirubicin—prostate cancer	5.74e-05	0.000639	CcSEcCtD
Carbinoxamine—Diarrhoea—Prednisone—prostate cancer	5.71e-05	0.000635	CcSEcCtD
Carbinoxamine—Decreased appetite—Epirubicin—prostate cancer	5.67e-05	0.000631	CcSEcCtD
Carbinoxamine—Hypotension—Doxorubicin—prostate cancer	5.64e-05	0.000627	CcSEcCtD
Carbinoxamine—Fatigue—Epirubicin—prostate cancer	5.62e-05	0.000626	CcSEcCtD
Carbinoxamine—Constipation—Epirubicin—prostate cancer	5.58e-05	0.00062	CcSEcCtD
Carbinoxamine—Nausea—Capecitabine—prostate cancer	5.56e-05	0.000619	CcSEcCtD
Carbinoxamine—Dizziness—Prednisone—prostate cancer	5.51e-05	0.000613	CcSEcCtD
Carbinoxamine—Insomnia—Doxorubicin—prostate cancer	5.46e-05	0.000607	CcSEcCtD
Carbinoxamine—Paraesthesia—Doxorubicin—prostate cancer	5.42e-05	0.000603	CcSEcCtD
Carbinoxamine—Feeling abnormal—Epirubicin—prostate cancer	5.37e-05	0.000598	CcSEcCtD
Carbinoxamine—Somnolence—Doxorubicin—prostate cancer	5.36e-05	0.000597	CcSEcCtD
Carbinoxamine—Dyspepsia—Doxorubicin—prostate cancer	5.31e-05	0.000591	CcSEcCtD
Carbinoxamine—Vomiting—Prednisone—prostate cancer	5.3e-05	0.00059	CcSEcCtD
Carbinoxamine—Decreased appetite—Doxorubicin—prostate cancer	5.25e-05	0.000584	CcSEcCtD
Carbinoxamine—Headache—Prednisone—prostate cancer	5.22e-05	0.000581	CcSEcCtD
Carbinoxamine—Fatigue—Doxorubicin—prostate cancer	5.2e-05	0.000579	CcSEcCtD
Carbinoxamine—Urticaria—Epirubicin—prostate cancer	5.18e-05	0.000576	CcSEcCtD
Carbinoxamine—Constipation—Doxorubicin—prostate cancer	5.16e-05	0.000574	CcSEcCtD
Carbinoxamine—Feeling abnormal—Doxorubicin—prostate cancer	4.97e-05	0.000553	CcSEcCtD
Carbinoxamine—Nausea—Prednisone—prostate cancer	4.95e-05	0.000551	CcSEcCtD
Carbinoxamine—Urticaria—Doxorubicin—prostate cancer	4.79e-05	0.000533	CcSEcCtD
Carbinoxamine—Chlorpromazine—CYP2E1—prostate cancer	4.78e-05	0.0266	CrCbGaD
Carbinoxamine—Asthenia—Epirubicin—prostate cancer	4.68e-05	0.000521	CcSEcCtD
Carbinoxamine—Diarrhoea—Epirubicin—prostate cancer	4.46e-05	0.000496	CcSEcCtD
Carbinoxamine—Clomipramine—CYP3A4—prostate cancer	4.39e-05	0.0245	CrCbGaD
Carbinoxamine—Asthenia—Doxorubicin—prostate cancer	4.33e-05	0.000482	CcSEcCtD
Carbinoxamine—Dizziness—Epirubicin—prostate cancer	4.31e-05	0.00048	CcSEcCtD
Carbinoxamine—Vomiting—Epirubicin—prostate cancer	4.15e-05	0.000461	CcSEcCtD
Carbinoxamine—Diarrhoea—Doxorubicin—prostate cancer	4.13e-05	0.000459	CcSEcCtD
Carbinoxamine—Headache—Epirubicin—prostate cancer	4.09e-05	0.000455	CcSEcCtD
Carbinoxamine—Dizziness—Doxorubicin—prostate cancer	3.99e-05	0.000444	CcSEcCtD
Carbinoxamine—Nausea—Epirubicin—prostate cancer	3.87e-05	0.000431	CcSEcCtD
Carbinoxamine—Vomiting—Doxorubicin—prostate cancer	3.84e-05	0.000427	CcSEcCtD
Carbinoxamine—Headache—Doxorubicin—prostate cancer	3.78e-05	0.000421	CcSEcCtD
Carbinoxamine—Orphenadrine—CYP3A4—prostate cancer	3.75e-05	0.0209	CrCbGaD
Carbinoxamine—Nausea—Doxorubicin—prostate cancer	3.58e-05	0.000399	CcSEcCtD
Carbinoxamine—Chlorpromazine—CYP3A4—prostate cancer	3.01e-05	0.0168	CrCbGaD
Carbinoxamine—CYP2C19—Metabolism—GGT1—prostate cancer	3.22e-06	3.47e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CYP2E1—prostate cancer	3.2e-06	3.45e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—NQO1—prostate cancer	3.19e-06	3.44e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—ITPR1—prostate cancer	3.19e-06	3.44e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—CXCL8—prostate cancer	3.19e-06	3.44e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—NCOA1—prostate cancer	3.18e-06	3.42e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—ERBB3—prostate cancer	3.17e-06	3.41e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—NQO1—prostate cancer	3.17e-06	3.41e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—FGFR2—prostate cancer	3.16e-06	3.41e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—TH—prostate cancer	3.15e-06	3.39e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.14e-06	3.38e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—CYP19A1—prostate cancer	3.13e-06	3.37e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—TH—prostate cancer	3.12e-06	3.36e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CYP3A4—prostate cancer	3.11e-06	3.36e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—MTHFR—prostate cancer	3.11e-06	3.35e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—LRP2—prostate cancer	3.11e-06	3.35e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PLCB2—prostate cancer	3.11e-06	3.35e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CYP2C18—prostate cancer	3.11e-06	3.35e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	3.1e-06	3.34e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CYP3A4—prostate cancer	3.09e-06	3.33e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.07e-06	3.31e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CYP1B1—prostate cancer	3.06e-06	3.3e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—PPARA—prostate cancer	3.05e-06	3.29e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—MTHFR—prostate cancer	3.05e-06	3.29e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—IL2—prostate cancer	3.05e-06	3.28e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—P4HB—prostate cancer	3.05e-06	3.28e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—TERT—prostate cancer	3.04e-06	3.27e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CYP1B1—prostate cancer	3.04e-06	3.27e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—RXRA—prostate cancer	3.02e-06	3.26e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—TYMS—prostate cancer	3.02e-06	3.25e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—PPARA—prostate cancer	2.99e-06	3.22e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—GSTM1—prostate cancer	2.98e-06	3.21e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—GGT1—prostate cancer	2.97e-06	3.2e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—SLC22A1—prostate cancer	2.96e-06	3.19e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—GGT1—prostate cancer	2.94e-06	3.17e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.94e-06	3.17e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—LPL—prostate cancer	2.93e-06	3.15e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—NCOA1—prostate cancer	2.92e-06	3.15e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—COMT—prostate cancer	2.91e-06	3.14e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—HIF1A—prostate cancer	2.9e-06	3.13e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—GSTP1—prostate cancer	2.9e-06	3.12e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—NCOA1—prostate cancer	2.9e-06	3.12e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—SULT2A1—prostate cancer	2.89e-06	3.11e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CYP19A1—prostate cancer	2.88e-06	3.1e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—CAV1—prostate cancer	2.87e-06	3.09e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CYP19A1—prostate cancer	2.85e-06	3.08e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—ITPR1—prostate cancer	2.85e-06	3.07e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—MED12—prostate cancer	2.84e-06	3.06e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—LEP—prostate cancer	2.83e-06	3.05e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—CYP1A1—prostate cancer	2.83e-06	3.05e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GNG5—prostate cancer	2.82e-06	3.04e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—CAV1—prostate cancer	2.81e-06	3.03e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CAV1—prostate cancer	2.81e-06	3.03e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—ERCC2—prostate cancer	2.8e-06	3.02e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.8e-06	3.02e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—RXRA—prostate cancer	2.78e-06	2.99e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—KDR—prostate cancer	2.78e-06	2.99e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—RXRA—prostate cancer	2.75e-06	2.97e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—NCOA3—prostate cancer	2.72e-06	2.93e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—ESR1—prostate cancer	2.71e-06	2.92e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—TYMS—prostate cancer	2.69e-06	2.9e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.68e-06	2.89e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—COMT—prostate cancer	2.68e-06	2.88e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—GSTP1—prostate cancer	2.66e-06	2.87e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—GSTM1—prostate cancer	2.66e-06	2.87e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—COMT—prostate cancer	2.65e-06	2.86e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—BAD—prostate cancer	2.64e-06	2.85e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—GSTP1—prostate cancer	2.64e-06	2.85e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—MTHFR—prostate cancer	2.63e-06	2.84e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—ITPR1—prostate cancer	2.62e-06	2.82e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—PIK3CG—prostate cancer	2.61e-06	2.82e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—LPL—prostate cancer	2.61e-06	2.81e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—ITPR1—prostate cancer	2.6e-06	2.8e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—HPGDS—prostate cancer	2.59e-06	2.79e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—PPARA—prostate cancer	2.59e-06	2.79e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CYP2C19—prostate cancer	2.57e-06	2.77e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—PIK3CG—prostate cancer	2.56e-06	2.76e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—APC—prostate cancer	2.56e-06	2.76e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—PIK3CG—prostate cancer	2.56e-06	2.76e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.55e-06	2.75e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—EGF—prostate cancer	2.53e-06	2.72e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—IRS1—prostate cancer	2.53e-06	2.72e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—CYP1A1—prostate cancer	2.52e-06	2.72e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GSTT1—prostate cancer	2.51e-06	2.71e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—ACHE—prostate cancer	2.51e-06	2.71e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—ERCC2—prostate cancer	2.5e-06	2.7e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CYP2A6—prostate cancer	2.48e-06	2.68e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—TYMS—prostate cancer	2.48e-06	2.67e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—INS—prostate cancer	2.48e-06	2.67e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—TYMS—prostate cancer	2.45e-06	2.65e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—GSK3B—prostate cancer	2.45e-06	2.65e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—GSTM1—prostate cancer	2.45e-06	2.64e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—CAV1—prostate cancer	2.43e-06	2.62e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—GSTM1—prostate cancer	2.43e-06	2.61e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—CREBBP—prostate cancer	2.42e-06	2.61e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—INS—prostate cancer	2.42e-06	2.61e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—INS—prostate cancer	2.42e-06	2.61e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—AKR1C3—prostate cancer	2.42e-06	2.6e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PRKACB—prostate cancer	2.4e-06	2.59e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—LPL—prostate cancer	2.4e-06	2.59e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—LPL—prostate cancer	2.38e-06	2.57e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CYP17A1—prostate cancer	2.38e-06	2.56e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—CREBBP—prostate cancer	2.37e-06	2.56e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CREBBP—prostate cancer	2.37e-06	2.56e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—MTHFR—prostate cancer	2.35e-06	2.53e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—IGF1—prostate cancer	2.34e-06	2.52e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—EGFR—prostate cancer	2.33e-06	2.51e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.32e-06	2.5e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CYP1A1—prostate cancer	2.32e-06	2.5e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—PPARA—prostate cancer	2.31e-06	2.49e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—ERCC2—prostate cancer	2.3e-06	2.48e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CYP1A1—prostate cancer	2.3e-06	2.48e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—PIK3CD—prostate cancer	2.3e-06	2.48e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—ERCC2—prostate cancer	2.28e-06	2.46e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—NCOA2—prostate cancer	2.27e-06	2.44e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—MAP2K1—prostate cancer	2.26e-06	2.44e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—PIK3CD—prostate cancer	2.25e-06	2.43e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—PIK3CD—prostate cancer	2.25e-06	2.42e-05	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—PIK3CA—prostate cancer	2.23e-06	2.4e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—SERPINE1—prostate cancer	2.22e-06	2.4e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—PIK3CG—prostate cancer	2.21e-06	2.39e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—KRAS—prostate cancer	2.2e-06	2.37e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—NOS3—prostate cancer	2.17e-06	2.34e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—CAV1—prostate cancer	2.17e-06	2.34e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—MTHFR—prostate cancer	2.16e-06	2.33e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—SLC5A5—prostate cancer	2.16e-06	2.33e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—FGF2—prostate cancer	2.15e-06	2.32e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—MTHFR—prostate cancer	2.14e-06	2.31e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—NOS3—prostate cancer	2.13e-06	2.29e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—NOS3—prostate cancer	2.12e-06	2.29e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—PPARA—prostate cancer	2.12e-06	2.29e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.11e-06	2.28e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—PPARA—prostate cancer	2.1e-06	2.27e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—INS—prostate cancer	2.1e-06	2.26e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—NQO1—prostate cancer	2.09e-06	2.25e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.07e-06	2.23e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—JAK2—prostate cancer	2.06e-06	2.22e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—TH—prostate cancer	2.06e-06	2.22e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—CREBBP—prostate cancer	2.05e-06	2.21e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—PIK3CA—prostate cancer	2.02e-06	2.18e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—MDM2—prostate cancer	2.01e-06	2.17e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—PIK3CB—prostate cancer	2e-06	2.16e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CYP1B1—prostate cancer	2e-06	2.16e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CAV1—prostate cancer	2e-06	2.15e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—ERBB2—prostate cancer	1.99e-06	2.14e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—PTGS2—prostate cancer	1.99e-06	2.14e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CAV1—prostate cancer	1.98e-06	2.13e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—PIK3CG—prostate cancer	1.98e-06	2.13e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—PIK3CB—prostate cancer	1.96e-06	2.11e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—PIK3CB—prostate cancer	1.96e-06	2.11e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—PIK3CD—prostate cancer	1.95e-06	2.1e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—PTGS2—prostate cancer	1.94e-06	2.1e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GGT1—prostate cancer	1.94e-06	2.09e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—NCOA1—prostate cancer	1.91e-06	2.06e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.89e-06	2.04e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CXCL8—prostate cancer	1.88e-06	2.03e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.88e-06	2.03e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—INS—prostate cancer	1.87e-06	2.02e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CDKN1B—prostate cancer	1.84e-06	1.98e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—NOS3—prostate cancer	1.84e-06	1.98e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—CREBBP—prostate cancer	1.83e-06	1.97e-05	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—AKT1—prostate cancer	1.82e-06	1.96e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.82e-06	1.96e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—RXRA—prostate cancer	1.82e-06	1.96e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CASP3—prostate cancer	1.8e-06	1.94e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—PIK3CG—prostate cancer	1.8e-06	1.94e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—IL2—prostate cancer	1.8e-06	1.94e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—IL6—prostate cancer	1.79e-06	1.93e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CCND1—prostate cancer	1.75e-06	1.89e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—COMT—prostate cancer	1.75e-06	1.89e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GSTP1—prostate cancer	1.74e-06	1.88e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CTNNB1—prostate cancer	1.74e-06	1.87e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—PIK3CD—prostate cancer	1.74e-06	1.87e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—PTEN—prostate cancer	1.73e-06	1.87e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—INS—prostate cancer	1.72e-06	1.85e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—ITPR1—prostate cancer	1.71e-06	1.85e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—INS—prostate cancer	1.71e-06	1.84e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—MMP9—prostate cancer	1.7e-06	1.84e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CDKN1A—prostate cancer	1.7e-06	1.83e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—PIK3CB—prostate cancer	1.7e-06	1.83e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—PTEN—prostate cancer	1.7e-06	1.83e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—PTEN—prostate cancer	1.69e-06	1.83e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CREBBP—prostate cancer	1.69e-06	1.82e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—PTGS2—prostate cancer	1.68e-06	1.81e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CREBBP—prostate cancer	1.67e-06	1.8e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—AKT1—prostate cancer	1.65e-06	1.78e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—EP300—prostate cancer	1.65e-06	1.78e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—NOS3—prostate cancer	1.64e-06	1.77e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—TYMS—prostate cancer	1.62e-06	1.74e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—EP300—prostate cancer	1.62e-06	1.74e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—EP300—prostate cancer	1.62e-06	1.74e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GSTM1—prostate cancer	1.6e-06	1.72e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.6e-06	1.72e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—PIK3CD—prostate cancer	1.58e-06	1.71e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—LPL—prostate cancer	1.57e-06	1.69e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—SRC—prostate cancer	1.57e-06	1.69e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—VEGFA—prostate cancer	1.53e-06	1.65e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.52e-06	1.63e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—STAT3—prostate cancer	1.51e-06	1.63e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—PIK3CB—prostate cancer	1.51e-06	1.63e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—NOS3—prostate cancer	1.51e-06	1.63e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—ERCC2—prostate cancer	1.5e-06	1.62e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—PTGS2—prostate cancer	1.5e-06	1.62e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—NOS3—prostate cancer	1.5e-06	1.61e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—PTEN—prostate cancer	1.47e-06	1.58e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—MTHFR—prostate cancer	1.41e-06	1.52e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—MYC—prostate cancer	1.41e-06	1.52e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—TGFB1—prostate cancer	1.4e-06	1.51e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—EP300—prostate cancer	1.4e-06	1.51e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.39e-06	1.5e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PPARA—prostate cancer	1.39e-06	1.5e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—PIK3CB—prostate cancer	1.38e-06	1.49e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—PTGS2—prostate cancer	1.38e-06	1.49e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—EGFR—prostate cancer	1.38e-06	1.48e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—PTGS2—prostate cancer	1.37e-06	1.47e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—PTEN—prostate cancer	1.31e-06	1.41e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CAV1—prostate cancer	1.3e-06	1.41e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—KRAS—prostate cancer	1.3e-06	1.4e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—EP300—prostate cancer	1.25e-06	1.34e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—PIK3CA—prostate cancer	1.22e-06	1.32e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—PTEN—prostate cancer	1.2e-06	1.3e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—PIK3CA—prostate cancer	1.2e-06	1.29e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—PIK3CA—prostate cancer	1.19e-06	1.29e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—PTEN—prostate cancer	1.19e-06	1.29e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.19e-06	1.28e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—TP53—prostate cancer	1.16e-06	1.25e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—EP300—prostate cancer	1.15e-06	1.24e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—EP300—prostate cancer	1.14e-06	1.23e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—INS—prostate cancer	1.12e-06	1.21e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CREBBP—prostate cancer	1.1e-06	1.19e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—IL6—prostate cancer	1.06e-06	1.14e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.04e-06	1.13e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—PIK3CA—prostate cancer	1.03e-06	1.11e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—AKT1—prostate cancer	9.98e-07	1.08e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—NOS3—prostate cancer	9.86e-07	1.06e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—AKT1—prostate cancer	9.77e-07	1.05e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—AKT1—prostate cancer	9.76e-07	1.05e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—PIK3CA—prostate cancer	9.23e-07	9.95e-06	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PIK3CB—prostate cancer	9.11e-07	9.81e-06	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PTGS2—prostate cancer	9.02e-07	9.72e-06	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—PIK3CA—prostate cancer	8.49e-07	9.15e-06	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—AKT1—prostate cancer	8.45e-07	9.1e-06	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—PIK3CA—prostate cancer	8.42e-07	9.07e-06	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PTEN—prostate cancer	7.87e-07	8.48e-06	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—AKT1—prostate cancer	7.54e-07	8.13e-06	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—EP300—prostate cancer	7.5e-07	8.09e-06	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—AKT1—prostate cancer	6.94e-07	7.47e-06	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—AKT1—prostate cancer	6.88e-07	7.41e-06	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PIK3CA—prostate cancer	5.55e-07	5.98e-06	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—AKT1—prostate cancer	4.53e-07	4.89e-06	CbGpPWpGaD
